Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences:

2024 RBC Capital Markets Global Healthcare Conference
Tuesday, May 14, 2024 at 10:00 a.m. ET in New York, NY

Bank of America Healthcare Conference 2024
Thursday, May 16, 2024 at 9:20 a.m. PT (12:20 p.m. ET) in Las Vegas, NV

A live and archived webcast of the presentations can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com .

Contact:

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Cameron Radinovic / Lee Roth
cradinovic@burnsmc.com / lroth@burnsmc.com
646-930-4406


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ITCI
The Conversation (0)

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the... Keep Reading...

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the... Keep Reading...

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting... Keep Reading...

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase CAPLYTA's strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product... Keep Reading...

Latest Press Releases

Related News